GlassScriptPhysician profile
Daniel J Finn
NPI 1568411064
$1,588.85
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $332.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $909.52 | 2019-2020 | |
| Abbvie INC. | $83.03 | 2019-2020 | |
| Astellas Pharma US INC | $79.62 | 2019-2020 | |
| Janssen Biotech, INC. | $78.36 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $72.46 | 2019 | |
| Pfizer INC. | $49.34 | 2019 | |
| Allergan, INC. | $48.96 | 2019-2020 | |
| Coloplast Corp | $47.28 | 2019-2020 | |
| Blue Earth Diagnostics | $41.66 | 2020 | |
| Dendreon Pharmaceuticals LLC | $23.22 | 2019 | |
| Neotract INC. | $22.86 | 2020 | |
| Boston Scientific Corporation | $19.99 | 2020 | |
| Dentsply Ih INC. | $19.82 | 2019 | |
| Axonics, INC. | $19.04 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $16.71 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.73 | 2019 | |
| Amgen INC. | $15.52 | 2019 | |
| Endo Pharmaceuticals INC. | $13.71 | 2019 | |
| Hollister Incorporated | $12.02 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Finn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.